The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire

Table 5

Incidence of grade 3-4 side effects with imatinib mesylate therapy (n = 42).

Toxicity	No. (%) with grades 3-4 toxicity
Non Hematologic toxicities
Bone or Joint aches	11 (26)
Others(a)	10 (24)
Skins rash	3 (7)
Nausea	2 (5)
Diarrhea	2 (5)
Muscle cramps	2 (5)
Hematologic toxicities
Granulocytopenia < 1⋅10^9/liter	14 (33)
Thrombocytopenia <50⋅10^9/liter	10 (24)
Anemia < 8 g/d liter	5 (12)

(a)2 with fever, 1 with neurological depression symptoms, and 1 with cardiac symptoms, fatigue 6.